No Data
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Last week, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) dengue vaccine, Qdenga, was approved in Indonesia for individuals six to 45 years of age.Qdenga is the only dengue vaccine approved in Indonesia fo
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
Finch Therapeutics Group Inc (NASDAQ:FNCH) will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Ltd (NYSE:TAK). Fo
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) met its primary endpoint
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.The data de
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from the prior year. Core earnings per share reached ¥425, up 1.2%.FY21 n
Takeda Pharmaceutical GAAP EPS of ¥425.00, revenue of ¥3.42T
Takeda Pharmaceutical press release (NYSE:TAK): FY GAAP EPS of ¥425.00.Revenue of ¥3.42T (+7.4% Y/Y).
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
Takeda Pharmaceutical Co Ltd (NYSE:TAK) shared new analyses of Livtencity (maribavir), including additional analyses from Phase 3 SOLSTICE trial data, which supported the FDA approval of Livtencity.Li
Takeda's Takhzyro meets goals of phase 3 trial in children ages 2 to
Takeda (NYSE:TAK) said a phase 3 study of Takhzyro for preventing hereditary angioedema (HAE) attacks in children ages two years to <12 years, met its goals. Takhzyro is approved for preventing re
Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection
Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID-19 in lab experiments.Icatibant bloc
Loading...
